136 related articles for article (PubMed ID: 2207312)
1. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors.
Foa R; Fierro MT; Raspadori D; Bonferroni M; Cardona S; Guarini A; Tos AG; di Celle PF; Cesano A; Matera L
Blood; 1990 Oct; 76(7):1349-54. PubMed ID: 2207312
[TBL] [Abstract][Full Text] [Related]
2. Distinct characteristics of lymphokine-activated killer (LAK) cells derived from patients with B-cell chronic lymphocytic leukemia (B-CLL). A factor in B-CLL serum promotes natural killer cell-like LAK cell growth.
Santiago-Schwarz F; Panagiotopoulos C; Sawitsky A; Rai KR
Blood; 1990 Oct; 76(7):1355-60. PubMed ID: 2207313
[TBL] [Abstract][Full Text] [Related]
3. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer cell functions in patients with leukemic B-lymphoproliferative diseases.
van der Harst D; Brand A; van Luxemburg-Heys SA; Kooy-Winkelaar EM; van Rood JJ
Blood; 1989 Nov; 74(7):2464-70. PubMed ID: 2804374
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
[TBL] [Abstract][Full Text] [Related]
7. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders.
Trentin L; Cerutti A; Zambello R; Sancretta R; Tassinari C; Facco M; Adami F; Rodeghiero F; Agostini C; Semenzato G
Blood; 1996 Apr; 87(8):3327-35. PubMed ID: 8605349
[TBL] [Abstract][Full Text] [Related]
11. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
[TBL] [Abstract][Full Text] [Related]
12. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
[TBL] [Abstract][Full Text] [Related]
14. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Hows JM; Goldman JM
Blood; 1990 Nov; 76(10):2037-45. PubMed ID: 2242425
[TBL] [Abstract][Full Text] [Related]
15. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A
Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
17. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani EM; Corneo G; Parmiani G
Ann Oncol; 1992 Feb; 3(2):155-62. PubMed ID: 1606087
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of lymphokine-activated killer cells against fresh human leukemia cells.
Tahara T; Iseki R; Morishima Y; Yokomaku S; Ohno R; Saito H
Jpn J Cancer Res; 1988 Mar; 79(3):390-9. PubMed ID: 3131287
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
Reiter Z; Taylor MW
Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
[TBL] [Abstract][Full Text] [Related]
20. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
